Unmet Needs in MCL
Frederick Locke, MD, addresses the ongoing unmet needs for patients with mantle cell lymphoma such as the role of novel agents in the upfront setting.
Future Directions for CAR T in MCL
Frederick Locke, MD, considers whether CAR T will gain a more significant role in mantle cell lymphoma and if it will move to the frontline setting.
Considerations for Treatment Selection in MCL
Frederick Locke, MD, explains when to choose CAR T over BTK inhibitors, patient factors to consider for CAR T cell therapy, and when BTK inhibitors are best utilized.
Role of CAR-T in MCL
Frederick Locke, MD, discusses the role of CAR T in patients with mantle cell lymphoma, the impact it has on autologous transplant, and when transplant is recommended.
ZUMA-2 Trial and Implications For CAR T in MCL
Frederick Locke, MD, discusses the ZUMA-2 trial, including the study design, results, and practical implications for CAR T in patients with mantle cell lymphoma.
Treatment Options for Mantle Cell Lymphoma (MCL)
Frederick Locke, MD, reviews the treatment options historically available to patients with mantle cell lymphoma who had disease recurrence after high-dose therapy and transplant.
CAR T Therapy and Durable Responses in MCL
Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.
How CAR T-Cell Therapy Has Evolved in Hematologic Malignancies
Frederick L. Locke, MD, discusses how chimeric antigen receptor (CAR) T-cell therapies have evolved over the last 30 years of research in the field of hematologic malignancies.
2 Clarke Drive Cranbury, NJ 08512